Hypocrellin B Exerts Its Antitumor Effect on Colorectal Cancer by Inhibiting the AKT Pathway
Journal of Natural Products · 2025
DOI: 10.1021/acs.jnatprod.4c01431 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Natural Products, 2025. Verfasst von Hongyan Qu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Yueqing Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325600, People's Republic of China. Hauptthemen laut MEDLINE: Quinones, Colorectal Neoplasms, Proto-Oncogene Proteins c-akt, Perylene. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Natural Science Foundation of Zhejiang Province, Special funding of Discipline Cluster of Oncology, Wenzhou Medical University, China, Wenzhou Science and Technology Project.
Abstract (Originalsprache)
Colorectal cancer is the fourth most common malignant cancer worldwide, with limited treatment options for advanced cases. The natural compound hypocrellin B has been shown to inhibit tumor growth, but its effects and specific mechanisms of action in colorectal cancer remain unclear. Here, we explore the anti-tumor effect of hypocrellin B on human colorectal cancer cells and identify molecular targets. We found that hypocrellin B significantly inhibits proliferation and migration and promotes apoptosis of colorectal cancer cells in vitro by targeting the AKT/STING signaling pathway. Hypocrellin B also inhibited tumor growth in vivo in a mouse xenograft model. In summary, hypocrellin B exerts an anticolorectal cancer effect by inhibiting the phosphorylation of AKT, thus blocking a key pathway of tumor growth and survival. These results indicate that hypocrellin B is a promising candidate for the treatment of colorectal cancer, warranting further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Affiliated Yueqing Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325600, People's Republic of China.
- The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325000, People's Republic of China.
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, People's Republic of China.
- The Institute of Life Sciences, Wenzhou University, Wenzhou, Zhejiang 325035, People's Republic of China.
ORCID-Profile: Suqing Zheng
Förderung
- Natural Science Foundation of Zhejiang Province
- Special funding of Discipline Cluster of Oncology, Wenzhou Medical University, China
- Wenzhou Science and Technology Project
- National Natural Science Funding of China
- Collaborative Education Project of Industry, University and Research Cooperation of the Ministry of Education
Zitieren
APA
Qu, H., Sun, A., Zhou, Y., Ma, C., Ye, Y., Xu, Y., Zhao, H., Zhao, C., Hu, Y., Yang, L., Peng, L., Zheng, S., & Wang, K. (2025). Hypocrellin B Exerts Its Antitumor Effect on Colorectal Cancer by Inhibiting the AKT Pathway. Journal of Natural Products. https://doi.org/10.1021/acs.jnatprod.4c01431
Vancouver
Qu H, Sun A, Zhou Y, Ma C, Ye Y, Xu Y, et al. Hypocrellin B Exerts Its Antitumor Effect on Colorectal Cancer by Inhibiting the AKT Pathway. Journal of Natural Products. 2025. doi:10.1021/acs.jnatprod.4c01431
BibTeX
@article{Qu2025,
author = {Qu, Hongyan and Sun, Aofeng and Zhou, Yi and Ma, Chunbo and Ye, Yihan and Xu, Yini and Zhao, Haiyang and Zhao, Chengguang and Hu, Yunming and Yang, Lehe and Peng, Lingcong and Zheng, Suqing and Wang, Ke},
title = {Hypocrellin B Exerts Its Antitumor Effect on Colorectal Cancer by Inhibiting the AKT Pathway},
journal = {Journal of Natural Products},
year = {2025},
doi = {10.1021/acs.jnatprod.4c01431}
}
EUVIMED